Edinburgh International Conference Centre The Exchange, EH3 8EE
Presentations
(click on the names to access to the presentations)
| Doctor Sally Killick: | Slider |
Program:
Paper of the Month
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
IPSS-R MDS Risk Assessment Calculator
Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator
MDS Fact Sheet
NICE Guideline
Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.
